Dec 8 2025
Join me (Geo) and guest speaker Dr. Nicole Zantek, MD, PhD, Medical Director of the Special Coagulation Laboratory and Professor, Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, as we discuss the pathophysiology of antiphospholipid antibodies and alternative methods to monitor warfarin and DOAC anticoagulation in patients diagnosed with APS. Click DOACs and Warfarin for the third of our three-part Coag Conversations series sponsored by BioMedica Diagnostics, Inc., of Windsor, Nova Scotia. The transcripts for presentations 1–3 are available from the BioMedica Diagnostics website.
Comments (1)
Anticoagulant Therapy
Hey GF, We don’t MONITOR DOACs…that implies a measured value is employed to make a potential dose adjustment. There is no supportive evidence for dose change(s), even if the result is outside the upper “on-therapy” range. We MEASURE DOACs, so the appropriate term should be used/applied.
From George, while the distinction may seem pedantic, my colleague Bob Gosselin is correct, we MONITOR warfarin therapy periodically to adjust the dosage because warfarin is affected by diet and coexistent medications. The dose-response of rivaroxaban, apixaban, and dabigatran is considered to be stable and reproducible, so we only MEASURE in limited circumstances.